The Lancet. Haematology
-
The Lancet. Haematology · Dec 2016
Randomized Controlled Trial Multicenter StudyAnticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
The efficacy and safety of anticoagulant treatment is not established for patients with acute symptomatic deep vein thrombosis (DVT) of the calf. We aimed to assess whether therapeutic anticoagulation is superior to placebo in patients with symptomatic calf DVT. ⋯ Swiss National Science Foundation, the Programme Hospitalier de Recherche Clinique in France, and the Canadian Institutes of Health Research.
-
The Lancet. Haematology · Dec 2016
Multicenter Study Clinical TrialAssociation between delivery methods for red blood cell transfusion and the risk of venous thromboembolism: a longitudinal study.
Mechanisms of red blood cell delivery and their contribution to the incidence of venous thromboembolism are not well understood in the clinical setting. We assessed whether red blood cell transfusion through peripherally inserted central catheters (PICCs) affects the risk of venous thromboembolism compared with transfusion through non-PICC devices. ⋯ Blue Cross Blue Shield of Michigan and Blue Care Network, as part of the BCBSM Value Partnerships program.
-
The Lancet. Haematology · Dec 2016
Multicenter StudyBortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Panobinostat (a pan histone deacetylase inhibitor) is approved in combination with bortezomib and dexamethasone for patients with relapsed multiple myeloma who have received two or more previous lines of therapy. We aimed to improve the safety of this combination and investigate efficacy by incorporating low-dose thalidomide, using sub-cutaneous weekly bortezomib, and determining the maximum tolerated dose of panobinostat in this regimen. ⋯ Novartis and Myeloma UK.